Management in patients with type 2 diabetes mellitus (DM) is aimed diabetic control required antidiabetic drugs(OAD). The aim of this study was to know data about the profile of diabetics control in patients with type 2 diabetesmellitus followed in department of endocrinology Arifin Achmad General Hospital Pekanbaru. The type of researchwas descriptive. The samples are 96 people included all patients with type 2 DM according to inclusion criteria. Theidentity patients and patients knowledge were determined using questionnaire, used of antidiabetics drugs and diabeticcontrol were detemined using medical record. The characteristics of patients with type 2 DM were most at group ofage 50-59 years (45,8%), female sex (58,3%), duration of DM 1-5 years (52,1%), complication of diabetic neuropathy(25%) and frequency of the Doctor once a month (64,6%). The used OAD predominant oral antidiabetic drugs (83%)combinations sulfonylureas and biguanid (73,7%), combinations oral antidiabetic drugs with insulin (14%) arecombinations biguanid with long acting insulin (69,2%) and intensive insulin (3%) are long acting insulin with rapidacting insulin (66,6%). Diabetic control of patients with type 2 DM are fasting blood glucose, post prandial 2 hoursblood glucose, total cholesterol, LDL and HDL was bad (68%, 74%, 46,9%, 61,5% and 70,8%). This researchshowed that used of antidiabetic drugs was not satisfactory of diabetic control.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.